<p><em><strong>Ginkgo Biloba in Cognitive and Neurological Health</strong></em></p>
<p><strong>TLDR</strong></p>
<p>Ginkgo biloba’s clinical significance in enhancing memory, alertness,<br>
and cognitive function was evaluated with focus on seizures, dementia,<br>
poor focus, memory issues, and brain fog. The review identified moderate<br>
benefits in memory enhancement and alertness, with inconsistent effects<br>
on seizure reduction and dementia symptoms. Evidence suggests potential<br>
cognitive support, though further validation is needed for widespread<br>
clinical use.</p>
<p><strong>Abstract</strong></p>
<p>This review synthesizes research on Ginkgo biloba clinical significance<br>
in modern medicine, focus on memory and alertness, seizures, dementia,<br>
poor focus, memory issues, brain fog to address the limited effective<br>
treatments for cognitive impairments and neuropsychiatric symptoms in<br>
aging and neurological disorders. The review aimed to evaluate clinical<br>
efficacy, benchmark trials on dementia and cognitive decline, identify<br>
neuroprotective mechanisms, compare safety profiles, and assess symptom<br>
management including seizures and brain fog. A systematic analysis of<br>
randomized controlled trials, meta-analyses, and mechanistic studies<br>
from Europe, Asia, and North America was conducted, emphasizing<br>
standardized extracts such as EGb 761. Findings indicate that Ginkgo<br>
biloba improves memory, attention, and executive function in mild<br>
cognitive impairment and dementia, with efficacy comparable to standard<br>
pharmacological agents and additive benefits in combination therapies.<br>
Neuroprotective effects involve antioxidant, anti-inflammatory, and<br>
mitochondrial protective mechanisms supported by preclinical and<br>
clinical evidence. Safety profiles are consistently favorable, with<br>
adverse events comparable to placebo and no significant bleeding risk.<br>
Evidence for managing seizures and brain fog remains limited but<br>
suggests potential benefits. Overall, Ginkgo biloba demonstrates<br>
promising therapeutic potential for cognitive and neuropsychiatric<br>
symptoms, warranting further high-quality standardized research to<br>
optimize clinical applications in neurodegenerative and cognitive<br>
disorders.</p>
<p><strong>Introduction</strong></p>
<p>Research on Ginkgo biloba clinical significance in modern medicine has<br>
emerged as a critical area of inquiry due to its potential to address<br>
cognitive impairments and neuropsychiatric symptoms prevalent in aging<br>
populations. Over the past decades, studies have evolved from early<br>
clinical trials demonstrating cognitive benefits in dementia and<br>
Alzheimer’s disease (AD) to more recent investigations exploring its<br>
effects on mild cognitive impairment (MCI), memory, and alertness (B,<br>
1998) [Pl et al., 1997](#citation-pl-et-al---1997) [Hort et al., 2023](#citation-hort-et-al---2023). The global increase in<br>
dementia cases, with neurodegenerative diseases posing significant<br>
health and economic burdens, underscores the practical importance of<br>
identifying effective, well-tolerated interventions (Barbalho et al.,<br>
2022) [Bohlken et al., 2024](#citation-bohlken-et-al---2024). Ginkgo biloba extracts, particularly<br>
standardized formulations like EGb 761®, have gained attention for their<br>
antioxidant, neuroprotective, and cerebrovascular properties, which may<br>
contribute to improved cognitive function and quality of life (Morató et<br>
al., 2024) [Kandiah et al., 2019](#citation-kandiah-et-al---2019).</p>
<p>Despite extensive research, the clinical efficacy of Ginkgo biloba in<br>
treating memory deficits, poor focus, brain fog, seizures, and dementia<br>
remains debated. Some meta-analyses and randomized controlled trials<br>
report significant cognitive and neuropsychiatric improvements with<br>
Ginkgo biloba extract, especially in mild to moderate dementia and MCI<br>
(Solfrizzi &amp; Panza, 2014) (Gauthier &amp; Schlaefke, 2014) (Hort et al.,<br>
2023). Conversely, other studies have found no significant benefits<br>
compared to placebo, highlighting inconsistencies possibly due to<br>
variations in diagnostic criteria, extract formulations, dosages, and<br>
study designs [McCarney et al., 2008](#citation-mccarney-et-al---2008) [Pagotto et al., 2024](#citation-pagotto-et-al---2024) (Yang et<br>
al., 2015). This controversy reflects a knowledge gap regarding the<br>
precise clinical indications, optimal dosing, and mechanisms underlying<br>
Ginkgo biloba’s effects on cognitive and neuropsychiatric symptoms<br>
[Kaschel, 2009](#citation-kaschel--2009) [Si et al., 2014](#citation-si-et-al---2014) [Özge et al., 2023](#citation--zge-et-al---2023). The consequences<br>
of this gap include uncertainty in clinical guidelines and<br>
underutilization of a potentially valuable therapeutic agent (Kandiah et<br>
al., 2019).</p>
<p>The conceptual framework guiding this review integrates the<br>
pharmacological actions of Ginkgo biloba—such as antioxidant activity,<br>
mitochondrial protection, and neurotransmitter modulation—with<br>
clinical outcomes in cognitive domains including memory, attention, and<br>
neuropsychiatric symptomatology [Liu et al., 2024](#citation-liu-et-al---2024) [Wang et al., 2021](#citation-wang-et-al---2021)<br>
[Peng et al., 2024](#citation-peng-et-al---2024). This framework links the biochemical properties of<br>
Ginkgo biloba extracts to their observed effects on cognitive impairment<br>
and dementia, providing a basis for evaluating clinical significance and<br>
therapeutic potential.</p>
<p>The purpose of this systematic review is to critically evaluate and<br>
synthesize current clinical evidence on the efficacy and safety of<br>
Ginkgo biloba in improving memory, alertness, seizures, dementia, poor<br>
focus, memory issues, and brain fog. By addressing inconsistencies and<br>
identifying effective clinical applications, this review aims to clarify<br>
Ginkgo biloba’s role in modern medicine and inform future research and<br>
clinical practice.</p>
<p>This review employs a comprehensive literature search and analysis of<br>
randomized controlled trials, systematic reviews, and meta-analyses<br>
focusing on standardized Ginkgo biloba extracts, with inclusion criteria<br>
emphasizing well-defined cognitive and neuropsychiatric outcomes.<br>
Findings are organized to elucidate clinical efficacy, safety profiles,<br>
and mechanistic insights, providing a structured synthesis of Ginkgo<br>
biloba’s therapeutic relevance.</p>
<p><strong>Purpose and Scope of the Review</strong></p>
<p><strong>Statement of Purpose</strong></p>
<p>The objective of this report is to examine the existing research on<br>
“Ginkgo biloba clinical significance in modern medicine, focus on<br>
memory and alertness, seizures, dementia, poor focus, memory issues,<br>
brain fog” in order to synthesize current evidence regarding its<br>
therapeutic potential and mechanisms of action. This review is important<br>
because cognitive impairments and neuropsychiatric symptoms represent<br>
significant challenges in aging populations and neurological disorders,<br>
with limited effective treatments available. By critically evaluating<br>
clinical trials, systematic reviews, and mechanistic studies, the report<br>
aims to clarify the efficacy, safety, and neuroprotective roles of<br>
Ginkgo biloba extracts, particularly in relation to memory enhancement,<br>
cognitive alertness, and management of dementia-related symptoms. The<br>
findings will inform future research directions and clinical<br>
applications in neurodegenerative and cognitive disorders.</p>
<p><strong>Specific Objectives:</strong></p>
<ul>
<li>
<p>To evaluate current knowledge on the clinical efficacy of Ginkgo<br>
biloba in improving memory, alertness, and cognitive function.</p>
</li>
<li>
<p>Benchmarking of existing clinical trials assessing Ginkgo biloba’s<br>
impact on dementia, neuropsychiatric symptoms, and cognitive decline.</p>
</li>
<li>
<p>Identification and synthesis of neuroprotective mechanisms underlying<br>
Ginkgo biloba’s effects on oxidative stress and neuroinflammation.</p>
</li>
<li>
<p>To compare safety profiles and tolerability of standardized Ginkgo<br>
biloba extracts across diverse patient populations.</p>
</li>
<li>
<p>To deconstruct the role of Ginkgo biloba in managing symptoms such as<br>
seizures, poor focus, and brain fog in neurological conditions.</p>
</li>
</ul>
<p><strong>Methodology of Literature Selection</strong></p>
<p><strong>Transformation of Query</strong></p>
<p>We take your original research question — <strong>“Ginkgo biloba clinical<br>
significance in modern medicine, focus on memory and alertness,<br>
seizures, dementia, poor focus, memory issues, brain fog”</strong>—and<br>
expand it into multiple, more specific search statements. By<br>
systematically expanding a broad research question into several targeted<br>
queries, we ensure that your literature search is both <strong>comprehensive</strong><br>
(you won’t miss niche or jargon‐specific studies) and <strong>manageable</strong><br>
(each query returns a set of papers tightly aligned with a particular<br>
facet of your topic).</p>
<p>Below were the transformed queries we formed from the original query:</p>
<ul>
<li>
<p>Ginkgo biloba clinical significance in modern medicine, focus on<br>
memory and alertness, seizures, dementia, poor focus, memory issues,<br>
brain fog</p>
</li>
<li>
<p>Investigate the neuroprotective effects of Ginkgo biloba in cognitive<br>
enhancement across neurodegenerative diseases, including Alzheimer’s<br>
and vascular dementia, with emphasis on mechanisms of action and<br>
clinical applications beyond memory improvement.</p>
</li>
<li>
<p>Explore the neuroprotective mechanisms of Ginkgo biloba in addressing<br>
inflammation, oxidative stress, and cognitive disorders, focusing on<br>
its clinical applications and efficacy in managing symptoms of<br>
Alzheimer’s disease, dementia, and cognitive impairments.</p>
</li>
<li>
<p>Investigate the role of Ginkgo biloba in managing cognitive decline<br>
and neuropsychiatric symptoms through its neuroprotective mechanisms,<br>
including effects on oxidative stress and neuroinflammation in diverse<br>
conditions beyond dementia.</p>
</li>
<li>
<p>Examine the impact of Ginkgo biloba extract on subjective cognitive<br>
decline in middle-aged adults, including its potential benefits for<br>
early cognitive impairment and differences in response compared to<br>
standard treatments for dementia.</p>
</li>
</ul>
<p><strong>Screening Papers</strong></p>
<p>We then run each of your transformed queries with the applied Inclusion<br>
&amp; Exclusion Criteria to retrieve a focused set of candidate papers for<br>
our always expanding database of over 270 million research papers.<br>
during this process we found 154 papers</p>
<p>Citation Chaining - Identifying additional relevant works</p>
<ul>
<li>
<p><strong>Backward Citation Chaining:</strong> For each of your core papers we<br>
examine its reference list to find earlier studies it draws upon. By<br>
tracing back through references, we ensure foundational work isn’t<br>
overlooked.</p>
</li>
<li>
<p><strong>Forward Citation Chaining:</strong> We also identify newer papers that have<br>
cited each core paper, tracking how the field has built on those<br>
results. This uncovers emerging debates, replication studies, and<br>
recent methodological advances</p>
</li>
</ul>
<p>A total of 58 additional papers are found during this process</p>
<p><strong>Relevance scoring and sorting</strong></p>
<p>We take our assembled pool of 212 candidate papers (154 from search<br>
queries + 58 from citation chaining) and impose a relevance ranking so<br>
that the most pertinent studies rise to the top of our final papers<br>
table. We found 206 papers that were relevant to the research query. Out<br>
of 206 papers, 50 were highly relevant.</p>
<p><strong>Results</strong></p>
<p><strong>Descriptive Summary of the Studies</strong></p>
<p>This section maps the research landscape of the literature on Ginkgo<br>
biloba clinical significance in modern medicine, focus on memory and<br>
alertness, seizures, dementia, poor focus, memory issues, brain fog,<br>
encompassing a broad spectrum of clinical trials, systematic reviews,<br>
meta-analyses, and mechanistic studies. The studies predominantly focus<br>
on cognitive impairments related to dementia, mild cognitive impairment,<br>
and neuropsychiatric symptoms, with a strong emphasis on the<br>
standardized extract EGb 761. Methodologies include randomized<br>
controlled trials, open-label studies, and network pharmacology<br>
analyses, with geographic representation spanning Europe, Asia, and<br>
North America. This comparative analysis is crucial for addressing the<br>
research questions concerning efficacy, safety, neuroprotective<br>
mechanisms, and symptom management of Ginkgo biloba in neurological<br>
conditions.</p>

<table>
<thead>
<tr>
<th>Study</th>
<th>Cognitive Improvement Measures</th>
<th>Neuroprotective Mechanism Assessment</th>
<th>Safety and Tolerability Profiles</th>
<th>Clinical Efficacy Benchmarking</th>
<th>Symptom Management Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>[S et al., 2023](#citation-s-et-al---2023)</td>
<td>Significant cognitive gains in AD patients with oxidative stress reduction</td>
<td>Antioxidant activity and oxidative load modulation</td>
<td>Well tolerated, no serious adverse events</td>
<td>Superior to standard management alone</td>
<td>Improved memory and alertness in AD</td>
</tr>
<tr>
<td>(“Ginkgo Biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review,” 2023)</td>
<td>Beneficial effects on memory, attention, executive function in mild NCD</td>
<td>Not detailed; focus on clinical outcomes</td>
<td>Safe with no increased adverse events</td>
<td>Effective versus placebo in mild NCD</td>
<td>Alleviated depression and anxiety symptoms</td>
</tr>
<tr>
<td>(Solfrizzi &amp; Panza, 2014)</td>
<td>Meta-analytic evidence supports cognition stabilization in dementia</td>
<td>Antioxidant and anti-inflammatory pathways implicated</td>
<td>Excellent tolerability at 240 mg/day dose</td>
<td>Comparable to cholinesterase inhibitors</td>
<td>Improved neuropsychiatric symptoms in dementia</td>
</tr>
<tr>
<td>(Napryeyenko &amp; Borzenko, 2011)</td>
<td>Cognitive and behavioral improvements in mild-moderate dementia</td>
<td>Not specified; clinical focus</td>
<td>Safe with no significant adverse events</td>
<td>EGb 761 superior to placebo</td>
<td>Reduced neuropsychiatric symptoms</td>
</tr>
<tr>
<td>[Ihl et al., 2010](#citation-ihl-et-al---2010)</td>
<td>Significant improvement in cognition and neuropsychiatric symptoms</td>
<td>Not specified; clinical trial data</td>
<td>Similar adverse event rates to placebo</td>
<td>EGb 761 better than placebo in dementia</td>
<td>Effective for neuropsychiatric symptoms</td>
</tr>
<tr>
<td>[Bachinskaya et al., 2011](#citation-bachinskaya-et-al---2011)</td>
<td>Alleviated behavioral symptoms in dementia patients</td>
<td>Not detailed; clinical symptom focus</td>
<td>Lower adverse events than placebo</td>
<td>Statistically significant symptom relief</td>
<td>Improved apathy, sleep, irritability</td>
</tr>
<tr>
<td>(Kasper &amp; Schubert, 2009)</td>
<td>Cognitive benefits comparable to donepezil in dementia</td>
<td>Interference with Abeta aggregation and mitochondrial dysfunction</td>
<td>Good safety profile</td>
<td>Comparable efficacy to donepezil</td>
<td>Beneficial for neuropsychiatric symptoms</td>
</tr>
<tr>
<td>[Kaschel, 2009](#citation-kaschel--2009)</td>
<td>Improved selective attention, executive function, long-term memory</td>
<td>Pharmacological actions on cognitive processes</td>
<td>Not emphasized</td>
<td>Evidence from multiple RCTs</td>
<td>Specific cognitive domains improved</td>
</tr>
<tr>
<td>[Mullaicharam, 2014](#citation-mullaicharam--2014)</td>
<td>Memory and cognitive speed improvements in brain health</td>
<td>Anti-inflammatory and antioxidant effects</td>
<td>Generally safe</td>
<td>Supportive evidence for cognitive enhancement</td>
<td>Improved alertness and memory</td>
</tr>
<tr>
<td>[McCarney et al., 2008](#citation-mccarney-et-al---2008)</td>
<td>No significant cognitive improvement in mild-moderate dementia</td>
<td>Not addressed</td>
<td>Safe, no major adverse events</td>
<td>No benefit over placebo</td>
<td>No symptom improvement observed</td>
</tr>
<tr>
<td>[Pl et al., 1997](#citation-pl-et-al---1997)</td>
<td>Modest cognitive stabilization and improvement in dementia</td>
<td>Not detailed; clinical efficacy focus</td>
<td>No significant safety concerns</td>
<td>EGb 761 better than placebo</td>
<td>Improved cognitive and social function</td>
</tr>
<tr>
<td>[B, 1998](#citation-b--1998)</td>
<td>Memory, concentration, alertness improved in dementia</td>
<td>Vasoactive and free radical scavenging properties</td>
<td>Side effects similar to placebo</td>
<td>Positive placebo-controlled study results</td>
<td>Early symptom relief in cognitive deficits</td>
</tr>
<tr>
<td>[Kanowski et al., 1996](#citation-kanowski-et-al---1996)</td>
<td>Significant cognitive and behavioral improvements in dementia</td>
<td>Not specified; clinical trial evidence</td>
<td>Well tolerated</td>
<td>EGb 761 superior to placebo</td>
<td>Improved attention and memory</td>
</tr>
<tr>
<td>[Loew, 2002](#citation-loew--2002)</td>
<td>Comparable efficacy to acetylcholinesterase inhibitors in dementia</td>
<td>Multifactorial action including blood flow and antioxidant</td>
<td>Favorable safety profile</td>
<td>Similar to standard antidementia drugs</td>
<td>Cognitive and functional benefits</td>
</tr>
<tr>
<td>[Bohlken et al., 2024](#citation-bohlken-et-al---2024)</td>
<td>Slower progression of dementia severity with Ginkgo biloba</td>
<td>Not detailed; real-world data analysis</td>
<td>Not specified</td>
<td>Reduced risk of dementia progression</td>
<td>Beneficial in mild and moderate dementia</td>
</tr>
<tr>
<td>[Liu et al., 2024](#citation-liu-et-al---2024)</td>
<td>Improved memory, cognition, behavior in neurological disorders</td>
<td>Free radical scavenging, anti-inflammatory, mitochondrial protection</td>
<td>Safety confirmed in clinical studies</td>
<td>Evidence from preclinical and clinical studies</td>
<td>Effective in depression, AD, stroke</td>
</tr>
<tr>
<td>[Morató et al., 2024](#citation-morat--et-al---2024)</td>
<td>Clinical efficacy in AD with cognitive improvements</td>
<td>Modulation of multiple AD pathophysiological targets</td>
<td>Good safety and tolerability</td>
<td>EGb 761 as herbal alternative to standard drugs</td>
<td>Cognitive decline management in AD</td>
</tr>
<tr>
<td>[Zhu et al., 2024](#citation-zhu-et-al---2024)</td>
<td>Cognitive function enhancement in AD animal models</td>
<td>PI3K/AKT/NF-κB pathway modulation</td>
<td>Not applicable (animal study)</td>
<td>Preclinical evidence supporting efficacy</td>
<td>Improved memory and neuronal morphology</td>
</tr>
<tr>
<td>[Chowdhury et al., 2024](#citation-chowdhury-et-al---2024)</td>
<td>Significant improvements in memory, executive function in neurocognitive disorder</td>
<td>Not detailed; clinical trial focus</td>
<td>Mild adverse events, well tolerated</td>
<td>Positive therapeutic benefits in Indian population</td>
<td>Improved cognitive and behavioral symptoms</td>
</tr>
<tr>
<td>[Pagotto et al., 2024](#citation-pagotto-et-al---2024)</td>
<td>Majority of trials show cognitive and neuropsychiatric improvements</td>
<td>Anti-inflammatory, antioxidant, neuroprotective effects</td>
<td>Safety generally confirmed</td>
<td>Mixed results; some trials show no difference</td>
<td>Improved MMSE, SKT, NPI scores</td>
</tr>
<tr>
<td>[Xia et al., 2024](#citation-xia-et-al---2024)</td>
<td>Cognitive improvement in AD rat model via mitochondrial protection</td>
<td>Regulation of oxidative stress and apoptosis proteins</td>
<td>Not applicable (animal study)</td>
<td>Preclinical support for neuroprotection</td>
<td>Protection against brain fog and memory loss</td>
</tr>
<tr>
<td>[Peng et al., 2024](#citation-peng-et-al---2024)</td>
<td>Therapeutic effects on cognitive and behavioral symptoms in AD</td>
<td>Anti-oxidant, neuroplasticity, neurotransmitter modulation</td>
<td>Few adverse reactions reported</td>
<td>Promising treatment option for AD</td>
<td>Improved memory and neuropsychiatric symptoms</td>
</tr>
<tr>
<td>[Liu et al., 2022](#citation-liu-et-al---2022)</td>
<td>Cognitive function improvement in AD mouse model</td>
<td>Restoration of lipid metabolism balance</td>
<td>Not applicable (animal study)</td>
<td>Comparable to donepezil in preclinical model</td>
<td>Alleviated memory and cognitive deficits</td>
</tr>
<tr>
<td>[Hort et al., 2023](#citation-hort-et-al---2023)</td>
<td>Cognitive and neuropsychiatric symptom improvement in mild NCD</td>
<td>Not detailed; clinical trial synthesis</td>
<td>Safe and well tolerated</td>
<td>Effective in mild neurocognitive disorder</td>
<td>Reduced depression and anxiety symptoms</td>
</tr>
<tr>
<td>[Li et al., 2023](#citation-li-et-al---2023)</td>
<td>Improved clinical effectiveness and memory with combination therapy</td>
<td>Not specified; meta-analysis focus</td>
<td>No increase in adverse reactions</td>
<td>Ginkgo plus donepezil superior to donepezil alone</td>
<td>Enhanced memory and daily living activities</td>
</tr>
<tr>
<td>[Özge et al., 2023](#citation--zge-et-al---2023)</td>
<td>Combination therapy slows dementia progression</td>
<td>Not detailed; clinical dataset analysis</td>
<td>Not specified</td>
<td>Combination with standard drugs more effective</td>
<td>Slower cognitive decline in AD and MCI</td>
</tr>
<tr>
<td>[Doepp, 2023](#citation-doepp--2023)</td>
<td>Improved brain performance and circulation in elderly</td>
<td>Blood thinning and cerebral blood flow enhancement</td>
<td>Recommended for older adults</td>
<td>Widely accepted in outpatient therapy</td>
<td>Improved alertness and cognitive function</td>
</tr>
<tr>
<td>[Jadhav et al., 2023](#citation-jadhav-et-al---2023)</td>
<td>Neuroprotective effects in CNS injuries and neurodegeneration</td>
<td>Free radical scavenging, neuroplasticity, anti-inflammatory</td>
<td>Not specified</td>
<td>Herbal supplement potential in brain disorders</td>
<td>Cognitive and memory improvements</td>
</tr>
<tr>
<td>(Öztürk &amp; Sari, 2023)</td>
<td>Cognitive and neurodegenerative disorder benefits</td>
<td>Antioxidant, anti-inflammatory, anticancer activities</td>
<td>Generally well tolerated</td>
<td>Supported by experimental and clinical research</td>
<td>Improved cognitive and psychiatric symptoms</td>
</tr>
<tr>
<td>[Kandiah et al., 2019](#citation-kandiah-et-al---2019)</td>
<td>Significant cognitive and behavioral improvements in dementia</td>
<td>Neuroprotective and cerebrovascular benefits</td>
<td>Positive risk-benefit profile</td>
<td>Comparable to acetylcholinesterase inhibitors</td>
<td>Effective in MCI and dementia symptoms</td>
</tr>
<tr>
<td>(Neuroprotective Effect of Ginkgo Biloba and Its Role in Alzheimer’s Disease, 2022)</td>
<td>Memory and cognitive function improvement in AD</td>
<td>Anti-amyloidogenic, anti-inflammatory, antioxidant effects</td>
<td>Not specified</td>
<td>Herbal medicine with neuroprotective effects</td>
<td>Improved memory and cognitive deficits</td>
</tr>
<tr>
<td>[Singh et al., 2022](#citation-singh-et-al---2022)</td>
<td>Beneficial effects on memory and cognitive function in AD</td>
<td>Antioxidant effects reducing endothelial damage</td>
<td>Not detailed</td>
<td>Supportive evidence for minor dementia treatment</td>
<td>Improved memory and alertness</td>
</tr>
<tr>
<td>[Barbalho et al., 2022](#citation-barbalho-et-al---2022)</td>
<td>Improved memory, cognition, and functional measures</td>
<td>Anti-inflammatory and oxidative stress reduction</td>
<td>Mild adverse effects reported</td>
<td>Effective in mild cognitive impairment and vascular cognitive impairment</td>
<td>Improved attention and memory</td>
</tr>
<tr>
<td>[Zheng et al., 2021](#citation-zheng-et-al---2021)</td>
<td>Comparable functional recovery to donepezil in AD</td>
<td>Brain activity modulation via rs-fMRI</td>
<td>Safe with no major adverse events</td>
<td>Comparable efficacy to donepezil</td>
<td>Improved neuropsychiatric symptoms</td>
</tr>
<tr>
<td>[Wang et al., 2021](#citation-wang-et-al---2021)</td>
<td>Cognitive and memory function improvement via network pharmacology</td>
<td>Multi-target effects including PI3K/AKT pathway</td>
<td>Not applicable</td>
<td>Mechanistic insights supporting clinical efficacy</td>
<td>Cognitive and behavioral symptom relief</td>
</tr>
<tr>
<td>[Kandiah et al., 2021](#citation-kandiah-et-al---2021)</td>
<td>Symptomatic improvement in MCI including cognition and anxiety</td>
<td>Neuroprotective and cerebrovascular effects</td>
<td>Safe and well tolerated</td>
<td>Recommended in clinical guidelines for MCI</td>
<td>Improved attention, memory, and anxiety</td>
</tr>
<tr>
<td>[Tomino et al., 2021](#citation-tomino-et-al---2021)</td>
<td>Cognitive and neuropsychiatric symptom improvement in MCI and dementia</td>
<td>Not specified; clinical review</td>
<td>Good safety profile</td>
<td>Combination therapy evidence limited</td>
<td>Reduced caregiver stress and improved autonomy</td>
</tr>
<tr>
<td>[Yang et al., 2015](#citation-yang-et-al---2015)</td>
<td>Potential cognitive and ADL improvements in MCI and AD</td>
<td>Not detailed; meta-analysis</td>
<td>Mild adverse events reported</td>
<td>Mixed but promising evidence</td>
<td>Improved memory and daily living activities</td>
</tr>
<tr>
<td>(Gauthier &amp; Schlaefke, 2014)</td>
<td>Significant cognitive and functional improvements in dementia</td>
<td>Not specified; meta-analysis of EGb 761 trials</td>
<td>Comparable adverse events to placebo</td>
<td>Level Ia evidence for EGb 761 efficacy</td>
<td>Effective in neuropsychiatric symptom relief</td>
</tr>
<tr>
<td>[Si et al., 2014](#citation-si-et-al---2014)</td>
<td>Improved neuropsychiatric symptoms and cognition in MCI</td>
<td>Not detailed; clinical trial focus</td>
<td>Non-serious adverse events similar to placebo</td>
<td>EGb 761 superior to placebo in MCI</td>
<td>Reduced anxiety and improved focus</td>
</tr>
</tbody>
</table><p><strong>Cognitive Improvement Measures:</strong></p>
<ul>
<li>
<p>38 studies reported significant improvements in memory, attention,<br>
executive function, or global cognition with Ginkgo biloba treatment,<br>
especially in mild cognitive impairment and dementia populations (S et<br>
al., 2023) (“Ginkgo Biloba Extract EGb 761 in the Treatment of<br>
Patients with Mild Neurocognitive Impairment: A Systematic<br>
Review,” 2023) (Solfrizzi &amp; Panza, 2014).</p>
</li>
<li>
<p>Some studies found no significant cognitive benefits compared to<br>
placebo, highlighting heterogeneity in outcomes possibly due to study<br>
design or patient selection [McCarney et al., 2008](#citation-mccarney-et-al---2008).</p>
</li>
<li>
<p>Improvements were often dose-dependent, with 240 mg/day frequently<br>
identified as the effective dose (Solfrizzi &amp; Panza, 2014) (Gauthier &amp;<br>
Schlaefke, 2014).</p>
</li>
</ul>
<p><strong>Neuroprotective Mechanism Assessment:</strong></p>
<ul>
<li>
<p>15 studies elucidated mechanisms including antioxidant activity, free<br>
radical scavenging, anti-inflammatory effects, mitochondrial<br>
protection, and modulation of signaling pathways such as<br>
PI3K/AKT/NF-κB [S et al., 2023](#citation-s-et-al---2023) [Liu et al., 2024](#citation-liu-et-al---2024) [Zhu et al., 2024](#citation-zhu-et-al---2024).</p>
</li>
<li>
<p>Network pharmacology and molecular docking studies supported<br>
multi-target synergistic effects on neurodegenerative disease pathways<br>
[Wang et al., 2021](#citation-wang-et-al---2021).</p>
</li>
<li>
<p>Several animal model studies provided preclinical evidence of<br>
neuroprotection via regulation of apoptosis and oxidative stress (Xia<br>
et al., 2024) [Liu et al., 2022](#citation-liu-et-al---2022).</p>
</li>
</ul>
<p><strong>Safety and Tolerability Profiles:</strong></p>
<ul>
<li>
<p>30 studies consistently reported good safety profiles with adverse<br>
events comparable to placebo, mostly mild and non-serious, including<br>
headache and gastrointestinal symptoms (“Ginkgo Biloba Extract EGb 761<br>
in the Treatment of Patients with Mild Neurocognitive Impairment: A<br>
Systematic Review,” 2023) [Ihl et al., 2010](#citation-ihl-et-al---2010) [Si et al., 2014](#citation-si-et-al---2014).</p>
</li>
<li>
<p>No significant increase in bleeding risk was observed despite<br>
theoretical concerns, supporting the favorable risk-benefit ratio<br>
[Kandiah et al., 2019](#citation-kandiah-et-al---2019).</p>
</li>
<li>
<p>Some studies noted lower adverse event rates in treatment groups<br>
compared to placebo [Bachinskaya et al., 2011](#citation-bachinskaya-et-al---2011).</p>
</li>
</ul>
<p><strong>Clinical Efficacy Benchmarking:</strong></p>
<ul>
<li>
<p>Multiple randomized controlled trials and meta-analyses demonstrated<br>
that Ginkgo biloba extract EGb 761 is comparable in efficacy to<br>
standard pharmacological treatments such as donepezil and<br>
cholinesterase inhibitors in dementia (Kasper &amp; Schubert, 2009)<br>
[Loew, 2002](#citation-loew--2002) [Zheng et al., 2021](#citation-zheng-et-al---2021).</p>
</li>
<li>
<p>Combination therapy with donepezil showed enhanced clinical<br>
effectiveness in some studies [Li et al., 2023](#citation-li-et-al---2023) [Özge et al., 2023](#citation--zge-et-al---2023).</p>
</li>
<li>
<p>Real-world data indicated slower progression of dementia severity with<br>
Ginkgo biloba prescriptions [Bohlken et al., 2024](#citation-bohlken-et-al---2024).</p>
</li>
</ul>
<p><strong>Symptom Management Outcomes:</strong></p>
<ul>
<li>
<p>Ginkgo biloba effectively alleviated neuropsychiatric symptoms<br>
including depression, anxiety, apathy, irritability, and sleep<br>
disturbances in dementia and mild cognitive impairment (Bachinskaya et<br>
al., 2011) [Si et al., 2014](#citation-si-et-al---2014).</p>
</li>
<li>
<p>Evidence for management of seizures and brain fog is limited but<br>
preclinical studies suggest potential benefits via neuroprotection and<br>
cognitive enhancement [Xia et al., 2024](#citation-xia-et-al---2024).</p>
</li>
<li>
<p>Improvements in poor focus and attention were reported in several<br>
clinical trials, supporting its role in cognitive symptom management<br>
[Kaschel, 2009](#citation-kaschel--2009) [Barbalho et al., 2022](#citation-barbalho-et-al---2022).</p>
</li>
</ul>
<p><strong>Critical Analysis and Synthesis</strong></p>
<p>The body of research on Ginkgo biloba’s clinical significance in<br>
memory, alertness, seizures, dementia, and related cognitive impairments<br>
reveals a generally positive therapeutic potential, particularly in<br>
dementia and mild cognitive impairment (MCI). Many studies demonstrate<br>
improvements in cognitive function, neuropsychiatric symptoms, and<br>
oxidative stress markers, supporting the neuroprotective role of<br>
standardized extracts like EGb 761. However, the literature also<br>
exhibits heterogeneity in study designs, diagnostic criteria, and<br>
outcome measures, which complicates direct comparisons and definitive<br>
conclusions. Safety profiles are consistently favorable, yet some trials<br>
report no significant benefits, highlighting the need for further<br>
high-quality, standardized research. Overall, the evidence suggests<br>
promising but not unequivocal efficacy, with mechanistic insights<br>
supporting antioxidant and anti-inflammatory actions.</p>

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Strengths</th>
<th>Weaknesses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Efficacy in Cognitive Improvement</td>
<td>Multiple randomized controlled trials (RCTs) and meta-analyses have demonstrated that Ginkgo biloba extracts, especially EGb 761, improve cognitive functions such as memory, attention, and executive function in patients with mild to moderate dementia and MCI. Significant improvements in neuropsychological tests and global ratings have been reported, with some studies showing comparable efficacy to standard drugs like donepezil (“Ginkgo Biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review,” 2023) (Napryeyenko &amp; Borzenko, 2011) (Kasper &amp; Schubert, 2009) [Kanowski et al., 1996](#citation-kanowski-et-al---1996) [Hort et al., 2023](#citation-hort-et-al---2023). The extract also alleviates neuropsychiatric symptoms, including depression and anxiety, enhancing quality of life [Bachinskaya et al., 2011](#citation-bachinskaya-et-al---2011) [Hort et al., 2023](#citation-hort-et-al---2023).</td>
<td>Despite positive findings, some large pragmatic trials and meta-analyses have reported no significant cognitive benefits over placebo, particularly in community settings or with lower doses [McCarney et al., 2008](#citation-mccarney-et-al---2008). Variability in diagnostic criteria and patient populations across studies limits generalizability. Additionally, some trials have methodological limitations such as small sample sizes, short durations, or lack of standardized outcome measures (“Ginkgo Biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review,” 2023) [Yang et al., 2015](#citation-yang-et-al---2015).</td>
</tr>
<tr>
<td>Neuroprotective Mechanisms and Biological Plausibility</td>
<td>Research elucidates multiple neuroprotective mechanisms of Ginkgo biloba, including antioxidant activity, free radical scavenging, anti-inflammatory effects, mitochondrial protection, and modulation of neurotransmitter systems. Network pharmacology and animal models support its role in reducing oxidative stress and apoptosis, particularly in Alzheimer’s disease (AD) models [Liu et al., 2024](#citation-liu-et-al---2024) [Xia et al., 2024](#citation-xia-et-al---2024) [Peng et al., 2024](#citation-peng-et-al---2024) [Wang et al., 2021](#citation-wang-et-al---2021). These mechanistic insights provide a strong biological rationale for its clinical effects on cognition and neuropsychiatric symptoms.</td>
<td>While mechanistic studies are robust, many are preclinical or based on in vitro/in vivo models, limiting direct translation to humans. The complexity and variability of Ginkgo biloba extracts complicate identification of active constituents and their precise molecular targets [Morató et al., 2024](#citation-morat--et-al---2024) [Morató et al., 2024](#citation-morat--et-al---2024). The heterogeneity of clinical trial results suggests that mechanisms may not uniformly translate into clinical efficacy across all patient groups.</td>
</tr>
<tr>
<td>Safety and Tolerability</td>
<td>Ginkgo biloba extracts, particularly EGb 761, have consistently demonstrated excellent safety profiles across diverse populations and long-term use. Adverse events are generally mild and comparable to placebo, with no significant increase in bleeding risk despite theoretical concerns (“Ginkgo Biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review,” 2023) [Ihl et al., 2010](#citation-ihl-et-al---2010) (Kasper &amp; Schubert, 2009) (Gauthier &amp; Schlaefke, 2014). This favorable risk-benefit ratio supports its use as a complementary or alternative therapy in cognitive disorders.</td>
<td>Some reports caution about potential interactions with anticoagulants and antiplatelet drugs, necessitating careful monitoring in polypharmacy contexts (Öztürk &amp; Sari, 2023). Additionally, the long-term safety beyond typical trial durations remains less well characterized, especially in vulnerable populations.</td>
</tr>
<tr>
<td>Methodological Quality and Study Design</td>
<td>The inclusion of multiple double-blind, placebo-controlled RCTs and systematic reviews strengthens the evidence base. Recent trials have applied standardized diagnostic criteria (e.g., DSM-5 for mild NCD), improving comparability (“Ginkgo Biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review,” 2023) [Hort et al., 2023](#citation-hort-et-al---2023). Meta-analyses have pooled data to assess efficacy and safety comprehensively (Gauthier &amp; Schlaefke, 2014).</td>
<td>Many studies suffer from methodological limitations such as inadequate blinding, small sample sizes, short follow-up periods, and inconsistent dosing regimens [Li et al., 2023](#citation-li-et-al---2023) [Yang et al., 2015](#citation-yang-et-al---2015). Earlier trials often lacked standardized diagnostic criteria, complicating retrospective analyses (“Ginkgo Biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review,” 2023). The heterogeneity in outcome measures and cognitive domains assessed reduces the ability to draw firm conclusions.</td>
</tr>
<tr>
<td>Comparative Effectiveness with Standard Pharmacological Treatments</td>
<td>Some studies indicate that Ginkgo biloba extract EGb 761 may have efficacy comparable to cholinesterase inhibitors like donepezil in improving cognitive and behavioral symptoms in dementia (Kasper &amp; Schubert, 2009) [Zheng et al., 2021](#citation-zheng-et-al---2021). Combination therapies with donepezil have shown additive benefits in some meta-analyses [Li et al., 2023](#citation-li-et-al---2023) [Özge et al., 2023](#citation--zge-et-al---2023). This positions Ginkgo biloba as a viable alternative or adjunct in dementia management.</td>
<td>Direct head-to-head comparisons are limited, and some trials show no significant differences between Ginkgo biloba and placebo or standard drugs [McCarney et al., 2008](#citation-mccarney-et-al---2008). The heterogeneity of patient populations and disease stages complicates assessment of relative efficacy. Evidence for combination therapy remains preliminary and requires further validation [Tomino et al., 2021](#citation-tomino-et-al---2021).</td>
</tr>
<tr>
<td>Management of Seizures, Poor Focus, and Brain Fog</td>
<td>While the primary focus has been on dementia and cognitive decline, some studies and reviews suggest potential benefits of Ginkgo biloba in improving attention, alertness, and executive functions, which may relate to symptoms like poor focus and brain fog [Kaschel, 2009](#citation-kaschel--2009) [B, 1998](#citation-b--1998). Its neuroprotective and vasoactive properties provide a plausible basis for such effects.</td>
<td>Direct clinical evidence specifically addressing seizures, brain fog, or poor focus in neurological conditions is sparse or anecdotal. Most studies focus on broader cognitive domains or dementia-related symptoms, limiting conclusions about these specific manifestations [Mullaicharam, 2014](#citation-mullaicharam--2014) [Sooby, 2005](#citation-sooby--2005). More targeted research is needed to clarify these roles.</td>
</tr>
<tr>
<td>Consistency and Generalizability of Findings</td>
<td>The consistency of positive findings across multiple populations, including mild cognitive impairment, Alzheimer’s disease, and vascular dementia, supports the generalizability of Ginkgo biloba’s benefits [Kandiah et al., 2019](#citation-kandiah-et-al---2019) [Barbalho et al., 2022](#citation-barbalho-et-al---2022). Real-world data also suggest slowed progression of dementia severity with Ginkgo biloba use [Bohlken et al., 2024](#citation-bohlken-et-al---2024).</td>
<td>Variability in extract formulations, dosages, and treatment durations across studies challenges the extrapolation of results to clinical practice. Differences in study populations, including ethnicity and comorbidities, may affect outcomes. Some negative or inconclusive trials highlight the need for standardized protocols and larger, well-powered studies [McCarney et al., 2008](#citation-mccarney-et-al---2008) [Pagotto et al., 2024](#citation-pagotto-et-al---2024).</td>
</tr>
</tbody>
</table><p><strong>Thematic Review of Literature</strong></p>
<p>Research on Ginkgo biloba’s clinical significance in modern medicine<br>
reveals several major themes centered on its impact on cognitive<br>
function, neuroprotective mechanisms, and safety profile. A substantial<br>
body of evidence supports its efficacy in improving memory, alertness,<br>
and mitigating neuropsychiatric symptoms particularly in dementia and<br>
mild cognitive impairment. The underlying neuroprotective actions<br>
frequently involve antioxidant, anti-inflammatory, and mitochondrial<br>
protective pathways. While most studies focus on dementia and cognitive<br>
decline, emerging research also addresses its role in managing symptoms<br>
such as seizures, poor focus, and brain fog, highlighting the need to<br>
further explore its broader neurological applications.</p>

<table>
<thead>
<tr>
<th>Theme</th>
<th>Appears In</th>
<th>Theme Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Efficacy in Cognitive Impairment and Dementia</td>
<td>38/50 Papers</td>
<td>Ginkgo biloba, especially the standardized extract EGb 761, consistently shows clinical benefits in improving memory, cognitive function, and neuropsychiatric symptoms in patients with mild cognitive impairment, Alzheimer’s disease, and vascular dementia. Multiple randomized controlled trials and meta-analyses demonstrate its capacity to stabilize or slow cognitive decline and improve daily functioning, often comparable to standard pharmacological treatments such as donepezil (“Ginkgo Biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review,” 2023) (Napryeyenko &amp; Borzenko, 2011) (Kasper &amp; Schubert, 2009) [Kanowski et al., 1996](#citation-kanowski-et-al---1996) [Pagotto et al., 2024](#citation-pagotto-et-al---2024) [Hort et al., 2023](#citation-hort-et-al---2023) [Kandiah et al., 2019](#citation-kandiah-et-al---2019).</td>
</tr>
<tr>
<td>Neuroprotective Mechanisms and Pharmacodynamics</td>
<td>30/50 Papers</td>
<td>The therapeutic effects of Ginkgo biloba are attributed to its antioxidant properties, reduction of oxidative stress, anti-inflammatory effects, mitochondrial protection, and modulation of neurotransmitter systems. Preclinical studies reveal its role in scavenging free radicals, regulating apoptotic pathways, and influencing signaling cascades such as PI3K/AKT/NF-κB, which underlie neurodegeneration and cognitive dysfunction [S et al., 2023](#citation-s-et-al---2023) [Liu et al., 2024](#citation-liu-et-al---2024) [Xia et al., 2024](#citation-xia-et-al---2024) [Peng et al., 2024](#citation-peng-et-al---2024) [Wang et al., 2021](#citation-wang-et-al---2021).</td>
</tr>
<tr>
<td>Safety and Tolerability Profile</td>
<td>29/50 Papers</td>
<td>Across diverse populations and clinical trial settings, Ginkgo biloba extracts demonstrate a favorable safety profile with adverse event rates comparable to placebo. Common side effects are mild and infrequent, supporting its suitability for long-term use in elderly and cognitively impaired patients, including those with comorbidities (“Ginkgo Biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review,” 2023) [Ihl et al., 2010](#citation-ihl-et-al---2010) [B, 1998](#citation-b--1998) [Chowdhury et al., 2024](#citation-chowdhury-et-al---2024) [Hort et al., 2023](#citation-hort-et-al---2023) (Gauthier &amp; Schlaefke, 2014).</td>
</tr>
<tr>
<td>Effects on Neuropsychiatric Symptoms and Behavioral Improvement</td>
<td>26/50 Papers</td>
<td>Ginkgo biloba extract EGb 761 significantly alleviates neuropsychiatric symptoms such as depression, anxiety, apathy, irritability, and sleep disturbances in dementia patients. Improvement in behavioral symptoms also reduces caregiver distress, enhancing overall patient and caregiver quality of life (Napryeyenko &amp; Borzenko, 2011) [Ihl et al., 2010](#citation-ihl-et-al---2010) [Bachinskaya et al., 2011](#citation-bachinskaya-et-al---2011) [Kandiah et al., 2019](#citation-kandiah-et-al---2019) [Si et al., 2014](#citation-si-et-al---2014).</td>
</tr>
<tr>
<td>Comparative Effectiveness with Standard Pharmacotherapies</td>
<td>15/50 Papers</td>
<td>Studies comparing Ginkgo biloba to cholinesterase inhibitors and NMDA receptor antagonists reveal comparable effectiveness in cognitive and functional outcomes, with some evidence suggesting additive benefits when used in combination therapy. However, findings on superiority or equivalence vary, emphasizing the need for further head-to-head trials (Kasper &amp; Schubert, 2009) [Loew, 2002](#citation-loew--2002) [Li et al., 2023](#citation-li-et-al---2023) [Zheng et al., 2021](#citation-zheng-et-al---2021).</td>
</tr>
<tr>
<td>Use in Mild Cognitive Impairment and Early Intervention</td>
<td>15/50 Papers</td>
<td>Ginkgo biloba is increasingly recognized for symptomatic treatment in mild cognitive impairment, with evidence indicating improvements in memory, attention, and executive function, and potential to delay progression to dementia. Expert consensus supports its inclusion in multidomain interventions for MCI (“Ginkgo Biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review,” 2023) [Hort et al., 2023](#citation-hort-et-al---2023) [Kandiah et al., 2021](#citation-kandiah-et-al---2021) [Tomino et al., 2021](#citation-tomino-et-al---2021).</td>
</tr>
<tr>
<td>Impact on Memory, Attention, and Cognitive Alertness</td>
<td>14/50 Papers</td>
<td>Chronic administration of Ginkgo biloba improves selective attention, long-term memory, and certain executive functions in both cognitively healthy individuals and those with impairment. Neuropsychological studies highlight specificity in cognitive domains positively affected by Ginkgo biloba extracts [Kaschel, 2009](#citation-kaschel--2009) [Kaschel, 2009](#citation-kaschel--2009) [B, 1998](#citation-b--1998) [Pagotto et al., 2024](#citation-pagotto-et-al---2024).</td>
</tr>
<tr>
<td>Effects on Seizures, Brain Fog, and Poor Focus</td>
<td>6/50 Papers</td>
<td>Although less extensively studied, some reports suggest Ginkgo biloba’s potential in managing neurological symptoms like seizures, brain fog, and poor concentration through its neuroprotective and antioxidative mechanisms. These findings warrant further focused clinical research [S et al., 2023](#citation-s-et-al---2023) [Mullaicharam, 2014](#citation-mullaicharam--2014) [Jadhav et al., 2023](#citation-jadhav-et-al---2023).</td>
</tr>
<tr>
<td>Pharmacokinetics, Bioavailability, and Chemical Composition</td>
<td>5/50 Papers</td>
<td>Research emphasizes the complexity of Ginkgo biloba extracts, particularly EGb 761, comprising flavonoids, terpenes, and other bioactive constituents. Understanding the pharmacokinetics and bioavailability of these compounds is crucial for optimizing therapeutic outcomes and standardizing clinical preparations [Morató et al., 2024](#citation-morat--et-al---2024) [Morató et al., 2024](#citation-morat--et-al---2024) (Shareena &amp; Kumar, 2022).</td>
</tr>
<tr>
<td>Geographic and Cultural Variations in Clinical Use</td>
<td>4/50 Papers</td>
<td>Studies conducted across diverse populations, including Asian, European, and Indian cohorts, demonstrate consistent efficacy and safety of Ginkgo biloba, although dosing strategies and clinical guidelines may vary regionally. Local expert consensus supports its tailored use in different clinical settings [Chowdhury et al., 2024](#citation-chowdhury-et-al---2024) [Doepp, 2023](#citation-doepp--2023) [Kandiah et al., 2019](#citation-kandiah-et-al---2019) [Kandiah et al., 2021](#citation-kandiah-et-al---2021).</td>
</tr>
</tbody>
</table><p><strong>Chronological Review of Literature</strong></p>
<p>Research on Ginkgo biloba’s clinical significance in modern medicine<br>
has evolved substantially over the past three decades, focusing<br>
initially on its efficacy for dementia and cognitive impairments. Early<br>
studies primarily investigated its effects on memory, alertness, and<br>
neuropsychiatric symptoms in dementia, establishing safety and modest<br>
cognitive benefits. Over time, research expanded to explore specific<br>
neuroprotective mechanisms, standardized extract formulations, and<br>
comparisons with conventional pharmacological treatments. Recent work<br>
emphasizes comprehensive molecular pathways, real-world effectiveness,<br>
and the role of Ginkgo biloba in managing mild cognitive impairment,<br>
seizures, brain fog, and other neurological conditions with a focus on<br>
safety and therapeutic optimization.</p>

<table>
<thead>
<tr>
<th>Year Range</th>
<th>Research Direction</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1996–2002</td>
<td>Foundational Clinical Trials and Early Efficacy</td>
<td>Initial randomized controlled trials demonstrated the safety and modest efficacy of Ginkgo biloba extract, primarily EGb 761, in stabilizing or improving cognitive performance and neuropsychiatric symptoms in Alzheimer’s disease, vascular dementia, and mixed dementias. Early studies also highlighted improvements in memory, concentration, and alertness with minimal side effects, setting the stage for further clinical investigation.</td>
</tr>
<tr>
<td>2004–2010</td>
<td>Systematic Reviews and Meta-Analyses of Cognitive Benefits</td>
<td>Systematic reviews and meta-analyses evaluated the effectiveness and tolerability of Ginkgo biloba in dementia and mild cognitive impairment, confirming modest cognitive and neuropsychiatric improvements. Comparative studies suggested efficacy comparable to cholinesterase inhibitors, with a favorable safety profile, while some large-scale trials yielded mixed results, prompting further research into dosage and patient selection.</td>
</tr>
<tr>
<td>2011–2015</td>
<td>Focus on Neuropsychiatric Symptoms and Mild Cognitive Impairment</td>
<td>Clinical trials concentrated on Ginkgo biloba’s ability to alleviate neuropsychiatric symptoms in dementia, including apathy, irritability, and depression. Studies also explored its role in mild cognitive impairment, demonstrating improvements in attention, executive function, and memory, with evidence supporting use in early stages of cognitive decline and emphasizing neuroprotective antioxidant effects.</td>
</tr>
<tr>
<td>2019–2021</td>
<td>Expert Consensus and Multimodal Mechanistic Insights</td>
<td>Expert groups issued consensus guidelines endorsing EGb 761 for symptomatic treatment of mild cognitive impairment and dementia, acknowledging its cerebrovascular and neuroprotective benefits. Research integrated pharmacodynamic studies with neuroimaging to elucidate brain activity changes and functional recovery, reinforcing its role alongside or as an alternative to conventional medications.</td>
</tr>
<tr>
<td>2022–2024</td>
<td>Molecular Mechanisms, Real-World Data, and Expanded Neurological Applications</td>
<td>Recent investigations focus on elucidating molecular pathways such as antioxidant, anti-inflammatory, and mitochondrial protective mechanisms underlying Ginkgo biloba’s effects. Real-world data supports its association with slowed dementia progression. Studies also examine its impact on seizures, brain fog, and cognitive dysfunction beyond dementia, optimizing formulations and combination therapies while confirming safety across diverse populations.</td>
</tr>
</tbody>
</table><p><strong>Agreement and Divergence Across Studies</strong></p>
<p>The body of research on Ginkgo biloba’s clinical significance broadly<br>
supports its efficacy in improving cognitive function, especially<br>
memory, attention, and neuropsychiatric symptoms in conditions like<br>
dementia and mild cognitive impairment (MCI). Most clinical trials and<br>
meta-analyses report favorable safety profiles and comparable efficacy<br>
to standard pharmacological treatments. However, some studies report<br>
null or inconsistent findings regarding cognitive benefits, possibly due<br>
to differences in dosage, duration, patient populations, and diagnostic<br>
criteria. There is emerging consensus about the neuroprotective<br>
mechanisms involving antioxidant, anti-inflammatory, and<br>
neurotransmitter-modulatory effects, though the exact pathways remain<br>
incompletely understood. Divergences often stem from methodological<br>
heterogeneity and variations in study design.</p>

<table>
<thead>
<tr>
<th>Comparison Criterion</th>
<th>Studies in Agreement</th>
<th>Studies in Divergence</th>
<th>Potential Explanations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cognitive Improvement Measures</td>
<td>Multiple randomized controlled trials (RCTs) and meta-analyses demonstrate significant improvement in memory, attention, executive function, and global cognition with Ginkgo biloba, particularly the EGb 761 extract at doses of 120-240 mg/day [S et al., 2023](#citation-s-et-al---2023) (“Ginkgo Biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review,” 2023) (Solfrizzi &amp; Panza, 2014) (Napryeyenko &amp; Borzenko, 2011) [Ihl et al., 2010](#citation-ihl-et-al---2010) (Kasper &amp; Schubert, 2009) [Kanowski et al., 1996](#citation-kanowski-et-al---1996) [Hort et al., 2023](#citation-hort-et-al---2023) (Gauthier &amp; Schlaefke, 2014). Improvements are noted in mild to moderate dementia and MCI, with positive effects on MMSE, ADAS-Cog, SKT, and other neuropsychological tests [Pl et al., 1997](#citation-pl-et-al---1997) [B, 1998](#citation-b--1998) [Yang et al., 2015](#citation-yang-et-al---2015).</td>
<td>Some trials, including large pragmatic community-based studies, found no significant cognitive benefits over placebo after 6 months, particularly at lower doses or in mild-moderate dementia [McCarney et al., 2008](#citation-mccarney-et-al---2008). Inconsistent findings also arise in systematic reviews due to heterogeneity in trial quality and patient selection [Birks, 2004](#citation-birks--2004) [Yang et al., 2015](#citation-yang-et-al---2015).</td>
<td>Variability in results is likely due to differences in study populations (severity and type of cognitive impairment), treatment duration, dosage, extract standardization, and diagnostic criteria. Earlier trials often lacked standardized definitions for MCI or dementia, complicating comparisons.</td>
</tr>
<tr>
<td>Neuroprotective Mechanism Assessment</td>
<td>There is consensus that Ginkgo biloba exerts neuroprotective effects through antioxidative, anti-inflammatory, mitochondrial protection, neurotransmitter regulation, and platelet-activating factor antagonism [S et al., 2023](#citation-s-et-al---2023) [Liu et al., 2024](#citation-liu-et-al---2024) [Morató et al., 2024](#citation-morat--et-al---2024) [Zhu et al., 2024](#citation-zhu-et-al---2024) [Peng et al., 2024](#citation-peng-et-al---2024) [Jadhav et al., 2023](#citation-jadhav-et-al---2023) [Wang et al., 2021](#citation-wang-et-al---2021). These mechanisms contribute to improved neuronal morphology, reduced oxidative stress, and cognitive function preservation in animal models and clinical settings [Xia et al., 2024](#citation-xia-et-al---2024) [Liu et al., 2022](#citation-liu-et-al---2022) [Chen et al., 2024](#citation-chen-et-al---2024).</td>
<td>Some reviews emphasize that while mechanisms are multifactorial, the precise molecular pathways remain incompletely elucidated, and clinical heterogeneity complicates precise mechanism-to-clinical benefit correlations [Morató et al., 2024](#citation-morat--et-al---2024) [Morató et al., 2024](#citation-morat--et-al---2024) (Neuroprotective Effect of Ginkgo Biloba and Its Role in Alzheimer’s Disease, 2022).</td>
<td>Differences arise from the complexity of Ginkgo biloba extracts, variability in phytochemical composition, and the challenge of translating preclinical mechanistic insights to heterogeneous clinical populations. Some studies focus on isolated compounds while others on whole extracts.</td>
</tr>
<tr>
<td>Safety and Tolerability Profiles</td>
<td>Most studies report that Ginkgo biloba, especially standardized extracts such as EGb 761, is well tolerated with adverse event rates comparable to placebo. Common side effects are mild and infrequent, including headache, gastrointestinal complaints, and dizziness (“Ginkgo Biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review,” 2023) (Napryeyenko &amp; Borzenko, 2011) (Kasper &amp; Schubert, 2009) [B, 1998](#citation-b--1998) [Kanowski et al., 1996](#citation-kanowski-et-al---1996) [Chowdhury et al., 2024](#citation-chowdhury-et-al---2024) [Hort et al., 2023](#citation-hort-et-al---2023) (Gauthier &amp; Schlaefke, 2014) [Si et al., 2014](#citation-si-et-al---2014). No significant bleeding risk has been confirmed despite theoretical concerns [Kandiah et al., 2019](#citation-kandiah-et-al---2019) [Barbalho et al., 2022](#citation-barbalho-et-al---2022).</td>
<td>A few studies mention isolated adverse events or caution with anticoagulant interactions, but no consistent safety concerns have been demonstrated (Öztürk &amp; Sari, 2023). Some older or low-quality studies report limited safety data [Birks, 2004](#citation-birks--2004).</td>
<td>Agreement reflects extensive clinical trial evidence and meta-analyses supporting safety; divergences may reflect case reports, small sample sizes, or incomplete adverse event reporting in earlier or non-standardized extracts.</td>
</tr>
<tr>
<td>Clinical Efficacy Benchmarking</td>
<td>Several studies and meta-analyses show that Ginkgo biloba extract EGb 761 is comparable to standard pharmacological agents like donepezil in efficacy for cognitive and neuropsychiatric symptoms in dementia and MCI (Kasper &amp; Schubert, 2009) [Loew, 2002](#citation-loew--2002) [Zheng et al., 2021](#citation-zheng-et-al---2021) (Gauthier &amp; Schlaefke, 2014). Combination therapy with cholinesterase inhibitors may offer additive benefits and slower cognitive decline [Li et al., 2023](#citation-li-et-al---2023) [Özge et al., 2023](#citation--zge-et-al---2023) [Tomino et al., 2021](#citation-tomino-et-al---2021).</td>
<td>Some trials find no significant difference between Ginkgo biloba and placebo or inconclusive comparative evidence against cholinesterase inhibitors [McCarney et al., 2008](#citation-mccarney-et-al---2008) [Birks, 2004](#citation-birks--2004) [Yang et al., 2015](#citation-yang-et-al---2015). Some suggest that benefits may be modest or limited to subgroups with neuropsychiatric symptoms [Kaschel, 2009](#citation-kaschel--2009).</td>
<td>Variations in study populations, treatment duration, outcome measures, and methodological rigor affect benchmarking. Positive findings often in well-defined neuropsychiatric subgroups and at adequate doses; negative findings often from pragmatic or shorter trials.</td>
</tr>
<tr>
<td>Symptom Management Outcomes</td>
<td>Evidence supports Ginkgo biloba’s role in alleviating neuropsychiatric symptoms such as apathy, depression, anxiety, irritability, sleep disturbances, and behavioral symptoms in dementia and MCI (Napryeyenko &amp; Borzenko, 2011) [Ihl et al., 2010](#citation-ihl-et-al---2010) [Bachinskaya et al., 2011](#citation-bachinskaya-et-al---2011) [Hort et al., 2023](#citation-hort-et-al---2023) [Kandiah et al., 2019](#citation-kandiah-et-al---2019). Improvements in brain fog, poor focus, and attention are also reported [Kaschel, 2009](#citation-kaschel--2009) [Mullaicharam, 2014](#citation-mullaicharam--2014) [Barbalho et al., 2022](#citation-barbalho-et-al---2022). There are some indications of benefit in seizure management though less robust data exist [Segura et al., 2000](#citation-segura-et-al---2000) [Jadhav et al., 2023](#citation-jadhav-et-al---2023).</td>
<td>Limited or no focused research on seizures, and few studies specifically quantify effects on brain fog or poor focus outside broader cognitive measures. Some trials report non-significant changes in global neuropsychiatric outcomes [McCarney et al., 2008](#citation-mccarney-et-al---2008) [Birks, 2004](#citation-birks--2004).</td>
<td>Symptom heterogeneity and measurement challenges contribute to variability. Most robust evidence is for neuropsychiatric symptom improvement in dementia; data on seizures and brain fog are preliminary or extrapolated from broader cognitive benefits. Further targeted studies are needed.</td>
</tr>
</tbody>
</table><p><strong>Theoretical and Practical Implications</strong></p>
<p><strong>Theoretical Implications</strong></p>
<ul>
<li>
<p>The synthesized evidence supports the neuroprotective and<br>
cognitive-enhancing effects of standardized Ginkgo biloba extracts,<br>
particularly EGb 761, in mild cognitive impairment (MCI), dementia,<br>
and Alzheimer’s disease (AD). These effects are theorized to arise<br>
from multifactorial mechanisms including antioxidant activity,<br>
anti-inflammatory responses, mitochondrial protection,<br>
neurotransmitter modulation, and vascular improvements, aligning with<br>
current neurodegenerative disease models that emphasize oxidative<br>
stress and neuroinflammation as key pathological processes (Liu et<br>
al., 2024) [Peng et al., 2024](#citation-peng-et-al---2024) [Wang et al., 2021](#citation-wang-et-al---2021).</p>
</li>
<li>
<p>The observed improvements in specific cognitive domains such as<br>
memory, attention, executive function, and neuropsychiatric symptoms<br>
suggest that Ginkgo biloba may exert selective effects on neural<br>
circuits involved in these functions. This specificity challenges the<br>
notion that herbal extracts have only generalized or placebo effects<br>
and supports a more nuanced pharmacodynamic profile involving<br>
modulation of neurotransmitter systems and neurovascular coupling<br>
[Kaschel, 2009](#citation-kaschel--2009) [Hort et al., 2023](#citation-hort-et-al---2023) [Barbalho et al., 2022](#citation-barbalho-et-al---2022).</p>
</li>
<li>
<p>The evidence indicating that Ginkgo biloba extract can slow dementia<br>
progression and stabilize cognitive decline provides theoretical<br>
support for its role as a disease-modifying agent rather than solely<br>
symptomatic treatment. This aligns with emerging theories that<br>
multi-target interventions may be necessary to address the complex<br>
pathophysiology of neurodegenerative diseases [Bohlken et al., 2024](#citation-bohlken-et-al---2024)<br>
[Özge et al., 2023](#citation--zge-et-al---2023) (Gauthier &amp; Schlaefke, 2014).</p>
</li>
<li>
<p>The heterogeneity in clinical trial outcomes and the dose-dependent<br>
efficacy observed in meta-analyses underscore the importance of<br>
standardized extract formulations and adequate dosing (notably 240<br>
mg/day) to achieve therapeutic effects. This supports pharmacological<br>
theories emphasizing the need for precise bioactive compound<br>
concentrations to elicit clinically meaningful responses (Solfrizzi &amp;<br>
Panza, 2014) (Gauthier &amp; Schlaefke, 2014) [Si et al., 2014](#citation-si-et-al---2014).</p>
</li>
<li>
<p>The neuropsychiatric symptom improvements and caregiver distress<br>
reduction associated with Ginkgo biloba treatment highlight its<br>
potential impact on behavioral and psychological symptoms of dementia<br>
(BPSD), suggesting that its mechanisms may extend beyond cognition to<br>
affect mood and behavior regulation pathways, consistent with<br>
neurochemical theories involving serotonin and dopamine systems<br>
[Bachinskaya et al., 2011](#citation-bachinskaya-et-al---2011) [Kandiah et al., 2019](#citation-kandiah-et-al---2019) [Si et al., 2014](#citation-si-et-al---2014).</p>
</li>
</ul>
<p><strong>Practical Implications</strong></p>
<ul>
<li>
<p>Clinically, Ginkgo biloba extract EGb 761® emerges as a viable<br>
therapeutic option for patients with MCI, mild to moderate dementia,<br>
and AD, offering cognitive and neuropsychiatric benefits with a<br>
favorable safety and tolerability profile. This supports its<br>
integration into treatment guidelines and clinical practice,<br>
especially for patients who are intolerant or have contraindications<br>
to conventional pharmacotherapies [Kandiah et al., 2019](#citation-kandiah-et-al---2019) (Hort et<br>
al., 2023) [Si et al., 2014](#citation-si-et-al---2014).</p>
</li>
<li>
<p>The evidence for Ginkgo biloba’s efficacy in combination with standard<br>
treatments such as donepezil suggests potential additive or<br>
synergistic effects, which could inform polypharmacy strategies aimed<br>
at optimizing cognitive and functional outcomes in dementia care (Li<br>
et al., 2023) [Zheng et al., 2021](#citation-zheng-et-al---2021) [Tomino et al., 2021](#citation-tomino-et-al---2021).</p>
</li>
<li>
<p>From a public health and policy perspective, the demonstrated safety<br>
and tolerability of Ginkgo biloba extracts, along with their<br>
over-the-counter availability in many regions, position them as<br>
accessible interventions that could reduce the burden of cognitive<br>
decline in aging populations, potentially delaying<br>
institutionalization and reducing healthcare costs [Doepp, 2023](#citation-doepp--2023)<br>
[Bohlken et al., 2024](#citation-bohlken-et-al---2024) (Öztürk &amp; Sari, 2023).</p>
</li>
<li>
<p>The need for further high-quality, large-scale randomized controlled<br>
trials to establish optimal dosing, long-term safety, and efficacy<br>
across diverse populations highlights a critical area for future<br>
research funding and regulatory focus, ensuring evidence-based use and<br>
standardization of Ginkgo biloba products [Pagotto et al., 2024](#citation-pagotto-et-al---2024) (Li<br>
et al., 2023) [Yang et al., 2015](#citation-yang-et-al---2015).</p>
</li>
<li>
<p>The mechanistic insights into Ginkgo biloba’s multi-target actions<br>
encourage pharmaceutical and nutraceutical industries to explore novel<br>
formulations and delivery systems that maximize bioavailability and<br>
therapeutic effects, fostering innovation in botanical drug<br>
development [Liu et al., 2024](#citation-liu-et-al---2024) [Morató et al., 2024](#citation-morat--et-al---2024) (Liu et al.,<br>
2022).</p>
</li>
<li>
<p>Finally, the positive impact on neuropsychiatric symptoms and<br>
caregiver burden underscores the importance of incorporating Ginkgo<br>
biloba into comprehensive dementia management programs that address<br>
both patient and caregiver quality of life, informing clinical care<br>
models and caregiver support policies [Bachinskaya et al., 2011](#citation-bachinskaya-et-al---2011)<br>
[Kandiah et al., 2019](#citation-kandiah-et-al---2019) [Si et al., 2014](#citation-si-et-al---2014).</p>
</li>
</ul>
<p><strong>Limitations of the Literature</strong></p>

<table>
<thead>
<tr>
<th>Area of Limitation</th>
<th>Description of Limitation</th>
<th>Papers which have limitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small Sample Sizes</td>
<td>Several studies suffer from limited sample sizes, which reduces statistical power and limits the generalizability of findings. Small cohorts increase the risk of type II errors and may not adequately represent diverse patient populations, affecting external validity.</td>
<td>[S et al., 2023](#citation-s-et-al---2023) [McCarney et al., 2008](#citation-mccarney-et-al---2008) [Si et al., 2014](#citation-si-et-al---2014)</td>
</tr>
<tr>
<td>Heterogeneity of Study Populations</td>
<td>Variability in patient characteristics, including dementia subtypes, severity, and presence of neuropsychiatric symptoms, introduces heterogeneity that complicates interpretation and comparison of results across studies. This limits the ability to draw firm conclusions about specific subgroups.</td>
<td>(Napryeyenko &amp; Borzenko, 2011) (Kasper &amp; Schubert, 2009) (Gauthier &amp; Schlaefke, 2014)</td>
</tr>
<tr>
<td>Methodological Constraints</td>
<td>Many trials exhibit methodological limitations such as inadequate blinding, use of unvalidated outcome measures, and early withdrawal biases. These constraints undermine the internal validity and reliability of the reported efficacy and safety outcomes.</td>
<td>(“Ginkgo Biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review,” 2023) [Birks, 2004](#citation-birks--2004) [Yang et al., 2015](#citation-yang-et-al---2015)</td>
</tr>
<tr>
<td>Short Duration of Follow-up</td>
<td>The majority of clinical trials have relatively short follow-up periods, often less than one year, which restricts assessment of long-term efficacy and safety. This temporal limitation impairs understanding of sustained benefits or adverse effects over time.</td>
<td>[Birks, 2004](#citation-birks--2004) [McCarney et al., 2008](#citation-mccarney-et-al---2008) [Pl et al., 1997](#citation-pl-et-al---1997)</td>
</tr>
<tr>
<td>Variability in Ginkgo biloba Preparations</td>
<td>Differences in extract formulations, dosages, and standardization across studies create inconsistencies that hinder direct comparison and meta-analytic synthesis. This variability affects reproducibility and clinical applicability of findings.</td>
<td>[Morató et al., 2024](#citation-morat--et-al---2024) [Morató et al., 2024](#citation-morat--et-al---2024) [Hort et al., 2023](#citation-hort-et-al---2023)</td>
</tr>
<tr>
<td>Limited Research on Seizures and Brain Fog</td>
<td>There is a paucity of focused clinical research investigating the effects of Ginkgo biloba on seizures, poor focus, and brain fog, resulting in insufficient evidence to support conclusions in these specific symptom domains.</td>
<td>[Mullaicharam, 2014](#citation-mullaicharam--2014) [Liu et al., 2024](#citation-liu-et-al---2024)</td>
</tr>
<tr>
<td>Geographic and Ethnic Bias</td>
<td>Most clinical trials have been conducted in European or East Asian populations, limiting the generalizability of findings to other ethnic groups and geographic regions. This bias may affect external validity due to genetic and environmental differences.</td>
<td>[Chowdhury et al., 2024](#citation-chowdhury-et-al---2024) [Kandiah et al., 2019](#citation-kandiah-et-al---2019)</td>
</tr>
</tbody>
</table><p><strong>Gaps and Future Research Directions</strong></p>

<table>
<thead>
<tr>
<th>Gap Area</th>
<th>Description</th>
<th>Future Research Directions</th>
<th>Justification</th>
<th>Research Priority</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heterogeneity in Clinical Trial Outcomes</td>
<td>Variability in cognitive efficacy results across trials, with some showing no significant benefit of Ginkgo biloba over placebo, especially in community settings or low doses [McCarney et al., 2008](#citation-mccarney-et-al---2008) [Birks, 2004](#citation-birks--2004).</td>
<td>Conduct large-scale, multicenter RCTs with standardized diagnostic criteria, dosing (≥240 mg/day), and outcome measures to clarify efficacy in diverse populations.</td>
<td>Resolving inconsistent findings is critical to establish clear clinical guidelines and optimize patient selection (“Ginkgo Biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review,” 2023) (Solfrizzi &amp; Panza, 2014) [McCarney et al., 2008](#citation-mccarney-et-al---2008).</td>
<td>High</td>
</tr>
<tr>
<td>Mechanistic Understanding of Neuroprotection</td>
<td>Limited elucidation of precise molecular targets and pathways by which Ginkgo biloba exerts neuroprotective effects in humans, despite preclinical evidence on antioxidant, anti-inflammatory, and signaling pathways like PI3K/AKT/NF-κB [Liu et al., 2024](#citation-liu-et-al---2024) [Zhu et al., 2024](#citation-zhu-et-al---2024) [Wang et al., 2021](#citation-wang-et-al---2021).</td>
<td>Integrate advanced molecular and imaging techniques in clinical studies to map active constituents’ effects on human neurobiology and validate preclinical mechanisms.</td>
<td>Improved mechanistic insight will enhance targeted therapeutic development and biomarker identification [Morató et al., 2024](#citation-morat--et-al---2024) [Peng et al., 2024](#citation-peng-et-al---2024).</td>
<td>High</td>
</tr>
<tr>
<td>Long-Term Safety and Drug Interaction Profiles</td>
<td>Insufficient data on long-term safety, especially regarding interactions with anticoagulants and polypharmacy in elderly patients (Öztürk &amp; Sari, 2023) [Kandiah et al., 2019](#citation-kandiah-et-al---2019).</td>
<td>Design longitudinal pharmacovigilance studies and drug interaction trials focusing on vulnerable populations with comorbidities and polypharmacy.</td>
<td>Ensuring safety over extended use is essential for clinical adoption and patient compliance [Ihl et al., 2010](#citation-ihl-et-al---2010) [Kandiah et al., 2019](#citation-kandiah-et-al---2019).</td>
<td>High</td>
</tr>
<tr>
<td>Efficacy in Seizures and Brain Fog</td>
<td>Sparse and mostly preclinical evidence on Ginkgo biloba’s role in managing seizures, brain fog, and poor focus symptoms [Xia et al., 2024](#citation-xia-et-al---2024) [Mullaicharam, 2014](#citation-mullaicharam--2014).</td>
<td>Conduct targeted clinical trials assessing Ginkgo biloba’s effects on seizure frequency, cognitive fog, and attentional deficits in relevant neurological disorders.</td>
<td>Addressing these understudied symptoms could expand therapeutic indications and improve quality of life [Kaschel, 2009](#citation-kaschel--2009) [Mullaicharam, 2014](#citation-mullaicharam--2014).</td>
<td>Medium</td>
</tr>
<tr>
<td>Optimal Dosage and Formulation</td>
<td>Lack of consensus on optimal dosing regimens and pharmaceutical formulations for maximal cognitive and neuropsychiatric benefits [Pagotto et al., 2024](#citation-pagotto-et-al---2024) [Pagotto et al., 2024](#citation-pagotto-et-al---2024).</td>
<td>Perform dose-ranging studies and compare different extract formulations (e.g., EGb 761 vs. others) to establish standardized treatment protocols.</td>
<td>Standardization is necessary to maximize efficacy and reproducibility across clinical settings (Solfrizzi &amp; Panza, 2014) [Hort et al., 2023](#citation-hort-et-al---2023).</td>
<td>High</td>
</tr>
<tr>
<td>Combination Therapy with Standard Drugs</td>
<td>Limited and inconclusive evidence on the additive or synergistic effects of Ginkgo biloba combined with cholinesterase inhibitors or memantine [Li et al., 2023](#citation-li-et-al---2023) [Özge et al., 2023](#citation--zge-et-al---2023) [Tomino et al., 2021](#citation-tomino-et-al---2021).</td>
<td>Conduct well-powered RCTs comparing monotherapy versus combination therapy with standardized outcome measures and long-term follow-up.</td>
<td>Clarifying combination benefits could optimize dementia management strategies and delay progression [Loew, 2002](#citation-loew--2002) [Özge et al., 2023](#citation--zge-et-al---2023).</td>
<td>Medium</td>
</tr>
<tr>
<td>Specific Cognitive Domain Effects</td>
<td>Insufficient data on differential effects of Ginkgo biloba on distinct cognitive domains such as executive function, selective attention, and memory subtypes [Kaschel, 2009](#citation-kaschel--2009) [Kaschel, 2009](#citation-kaschel--2009).</td>
<td>Design neuropsychological trials with comprehensive, domain-specific cognitive batteries to delineate precise cognitive benefits.</td>
<td>Understanding domain specificity will guide personalized treatment and outcome assessment [Kaschel, 2009](#citation-kaschel--2009).</td>
<td>Medium</td>
</tr>
<tr>
<td>Biomarkers for Treatment Response</td>
<td>Absence of validated biomarkers to predict or monitor response to Ginkgo biloba treatment in cognitive disorders [Zheng et al., 2021](#citation-zheng-et-al---2021) [Morató et al., 2024](#citation-morat--et-al---2024).</td>
<td>Develop and validate neuroimaging, biochemical, and genetic biomarkers correlated with clinical outcomes in Ginkgo biloba trials.</td>
<td>Biomarkers would enable precision medicine approaches and early identification of responders [Zheng et al., 2021](#citation-zheng-et-al---2021) [Morató et al., 2024](#citation-morat--et-al---2024).</td>
<td>High</td>
</tr>
<tr>
<td>Effects in Diverse Ethnic and Geographic Populations</td>
<td>Underrepresentation of certain populations (e.g., Indian, Asian) in clinical trials limits generalizability [Chowdhury et al., 2024](#citation-chowdhury-et-al---2024) [Kandiah et al., 2021](#citation-kandiah-et-al---2021).</td>
<td>Expand clinical research to include diverse ethnic groups with culturally adapted protocols to assess efficacy and safety.</td>
<td>Enhancing inclusivity ensures broader applicability and addresses population-specific responses [Chowdhury et al., 2024](#citation-chowdhury-et-al---2024) [Kandiah et al., 2021](#citation-kandiah-et-al---2021).</td>
<td>Medium</td>
</tr>
<tr>
<td>Longitudinal Impact on Dementia Progression</td>
<td>Limited real-world evidence on the long-term impact of Ginkgo biloba on slowing dementia progression beyond 1-2 years [Bohlken et al., 2024](#citation-bohlken-et-al---2024) [Özge et al., 2023](#citation--zge-et-al---2023).</td>
<td>Implement prospective cohort studies and registries with extended follow-up to evaluate disease-modifying potential.</td>
<td>Long-term data are crucial to justify chronic use and healthcare policy decisions [Bohlken et al., 2024](#citation-bohlken-et-al---2024) [Özge et al., 2023](#citation--zge-et-al---2023).</td>
<td>High</td>
</tr>
</tbody>
</table><p><strong>Overall Synthesis and Conclusion</strong></p>
<p>The comprehensive body of literature on Ginkgo biloba, particularly the<br>
standardized extract EGb 761, underscores its meaningful clinical<br>
significance in modern medicine for cognitive impairments, with a<br>
primary focus on memory enhancement, alertness, and neuropsychiatric<br>
symptom management in conditions such as dementia and mild cognitive<br>
impairment (MCI). Across numerous randomized controlled trials,<br>
meta-analyses, and systematic reviews, Ginkgo biloba consistently<br>
demonstrates beneficial effects on cognitive functions including memory,<br>
attention, executive function, and processing speed. These effects have<br>
been observed especially in patients with Alzheimer’s disease, vascular<br>
dementia, and mild neurocognitive disorders. Importantly, many studies<br>
report that cognitive improvements with Ginkgo biloba are comparable to<br>
those achieved with standard pharmacological agents such as<br>
cholinesterase inhibitors and donepezil, positioning it as a viable<br>
alternative or adjunctive therapy for dementia symptom management.</p>
<p>Mechanistically, the therapeutic potential of Ginkgo biloba is supported<br>
by robust preclinical and clinical evidence highlighting its<br>
multifaceted neuroprotective actions. These include potent antioxidant<br>
and free radical scavenging activities, anti-inflammatory effects,<br>
mitochondrial protection, modulation of neurotransmitter systems, and<br>
regulation of signaling pathways such as PI3K/AKT/NF-κB. Such mechanisms<br>
contribute to reduced oxidative stress, apoptosis inhibition, and<br>
improved neuronal morphology and function, providing a strong biological<br>
rationale for its cognitive benefits. Furthermore, network pharmacology<br>
analyses reveal that Ginkgo biloba’s multicomponent nature allows it to<br>
target multiple pathophysiological processes relevant to<br>
neurodegenerative diseases.</p>
<p>Safety and tolerability profiles are favorable and well-established,<br>
with adverse events generally mild and comparable to placebo. Although<br>
theoretical concerns about bleeding risks exist, clinical data do not<br>
support significant safety issues, even in polypharmacy contexts. This<br>
positive risk-benefit ratio renders Ginkgo biloba an attractive option<br>
for long-term management of cognitive decline.</p>
<p>While evidence supports its efficacy in improving neuropsychiatric<br>
symptoms such as depression, anxiety, apathy, and sleep disturbances,<br>
research specifically addressing its role in seizures, brain fog, and<br>
poor focus remains limited and warrants further targeted investigation.<br>
Methodological heterogeneity and variability in study designs, patient<br>
populations, and dosing regimens temper the generalizability of<br>
findings, emphasizing the need for standardized, high-quality trials.<br>
Nonetheless, real-world data suggest that Ginkgo biloba may slow<br>
dementia progression, especially when used early or in combination with<br>
other treatments.</p>
<p>In sum, the literature presents Ginkgo biloba, especially EGb 761, as a<br>
well-tolerated, neuroprotective agent with clinically meaningful<br>
benefits for cognitive enhancement and symptom management in dementia<br>
and mild cognitive impairment. Its multimodal mechanisms and comparable<br>
efficacy to standard treatments support its integration into therapeutic<br>
strategies for neurodegenerative disorders, although further research is<br>
needed to clarify its full potential in specific symptoms such as<br>
seizures and brain fog.</p>
<p><strong>References</strong></p>
<p>B, S. (1998). Clinical improvement of memory and other cognitive<br>
functions by Ginkgo biloba: review of relevant literature.<em>Advances in<br>
Therapy</em>.</p>
<p>Pl, L. B., Katz, M. M., Berman, N., Itil, T. M., Freedman, A. M., &amp;<br>
Schatzberg, A. F. (1997). A placebo-controlled, double-blind, randomized<br>
trial of an extract of Ginkgo biloba for dementia. North American EGb<br>
Study Group.<em>JAMA</em>. <a href="https://doi.org/10.1001/JAMA.278.16.1327">https://doi.org/10.1001/JAMA.278.16.1327</a></p>
<p>Hort, J., Duning, T., &amp; Hoerr, R. (2023). Ginkgo biloba Extract EGb 761<br>
in the Treatment of Patients with Mild Neurocognitive Impairment: A<br>
Systematic Review.<em>Neuropsychiatric Disease and Treatment</em>.<br>
<a href="https://doi.org/10.2147/NDT.S401231">https://doi.org/10.2147/NDT.S401231</a></p>
<p>Barbalho, S. M., Direito, R., Laurindo, L. F., Marton, L. T., Guiguer,<br>
E. L., Goulart, R. de A., Tofano, R. J., Carvalho, A. de C. A. de,<br>
Flato, U. A. P., Tofano, V. A. C., Detregiachi, C. R. P., Bueno, P. C.<br>
dos S., Girio, R. J. S., &amp; Araújo, A. C. (2022). Ginkgo biloba in the<br>
Aging Process: A Narrative Review.<em>Antioxidants</em>.<br>
<a href="https://doi.org/10.3390/antiox11030525">https://doi.org/10.3390/antiox11030525</a></p>
<p>Bohlken, J., Hajek, A., Burkart, M., &amp; Kostev, K. (2024). Ginkgo biloba<br>
Extract Prescriptions Are Associated with Slower Progression of Dementia<br>
Severity—Analysis of Longitudinal Real-World Data.<em>Brain Sciences</em>.<br>
<a href="https://doi.org/10.3390/brainsci15010012">https://doi.org/10.3390/brainsci15010012</a></p>
<p>Morató, X., Tartari, J. P., Pytel, V. V., &amp; Boada, M. (2024b).<br>
Pharmacodynamic and Clinical Effects of Ginkgo Biloba Extract EGb 761<br>
and Its Phytochemical Components in Alzheimer’s Disease.<em>Journal of<br>
Alzheimer’s Disease</em>. <a href="https://doi.org/10.3233/jad-231372">https://doi.org/10.3233/jad-231372</a></p>
<p>Kandiah, N., Ong, P. A., Yuda, T., Ng, L.-L., Mamun, K., Merchant, R.<br>
A., Chen, C., Dominguez, J. C., Marasigan, S., Ampil, E., Nguyen, V. T.,<br>
Yusoff, S., Chan, Y. F., Yong, F. M., Krairit, O., Suthisisang, C.,<br>
Senanarong, V., Ji, Y., Thukral, R., &amp; Ihl, R. (2019). Treatment of<br>
dementia and mild cognitive impairment with or without cerebrovascular<br>
disease: Expert consensus on the use of Ginkgo biloba extract, EGb<br>
761®.<em>CNS Neuroscience &amp; Therapeutics</em>.<br>
<a href="https://doi.org/10.1111/CNS.13095">https://doi.org/10.1111/CNS.13095</a></p>
<p>Solfrizzi, V., &amp; Panza, F. (2014). Plant-based nutraceutical<br>
interventions against cognitive impairment and dementia: Meta-analytic<br>
evidence of efficacy of a standardized Gingko biloba extract.<em>Journal of<br>
Alzheimer’s Disease</em>. <a href="https://doi.org/10.3233/JAD-141887">https://doi.org/10.3233/JAD-141887</a></p>
<p>Gauthier, S., &amp; Schlaefke, S. (2014). Efficacy and tolerability of<br>
Ginkgo biloba extract EGb 761® in dementia: a systematic review and<br>
meta-analysis of randomized placebo-controlled trials.<em>Clinical<br>
Interventions in Aging</em>. <a href="https://doi.org/10.2147/CIA.S72728">https://doi.org/10.2147/CIA.S72728</a></p>
<p>McCarney, R., Fisher, P., Iliffe, S., Haselen, R. van, Griffin, M.,<br>
Meulen, J. van der, &amp; Warner, J. (2008). Ginkgo biloba for mild to<br>
moderate dementia in a community setting: a pragmatic, randomised,<br>
parallel‐group, double‐blind, placebo‐controlled trial.<em>International<br>
Journal of Geriatric Psychiatry</em>. <a href="https://doi.org/10.1002/GPS.2055">https://doi.org/10.1002/GPS.2055</a></p>
<p>Pagotto, G. L. de O., Santos, L. A. da S., Osman, N., Lamas, C.,<br>
Laurindo, L. F., Pomini, K. T., Guissoni, L. M., Lima, E., Goulart, R.<br>
de Á., Catharin, V. M. C. S., Direito, R., Tanaka, M., &amp; Barbalho, S. M.<br>
(2024a). Ginkgo biloba: A Leaf of Hope in the Fight against Alzheimer’s<br>
Dementia: Clinical Trial Systematic Review.<em>Antioxidants</em>.<br>
<a href="https://doi.org/10.3390/antiox13060651">https://doi.org/10.3390/antiox13060651</a></p>
<p>Yang, G., Wang, Y.-Y., Sun, J., Zhang, K., &amp; Liu, J. (2015). Ginkgo<br>
Biloba for Mild Cognitive Impairment and Alzheimer’s Disease: A<br>
Systematic Review and Meta-Analysis of Randomized Controlled<br>
Trials.<em>Current Topics in Medicinal Chemistry</em>.<br>
<a href="https://doi.org/10.2174/1568026615666150813143520">https://doi.org/10.2174/1568026615666150813143520</a></p>
<p>Kaschel, R. (2009a).<em>Ginkgo biloba: specificity of neuropsychological<br>
improvement—a selective review in search of differential effects</em>.<br>
<a href="https://doi.org/10.1002/hup.1037">https://doi.org/10.1002/hup.1037</a></p>
<p>Si, G., Preuss, U. W., Wong, J. W. M., Hoerr, R., Kaschel, R., &amp;<br>
Bachinskaya, N. (2014). Efficacy and safety of Ginkgo biloba extract EGb<br>
761 in mild cognitive impairment with neuropsychiatric symptoms: a<br>
randomized, placebo-controlled, double-blind, multi-center<br>
trial.<em>International Journal of Geriatric Psychiatry</em>.<br>
<a href="https://doi.org/10.1002/GPS.4103">https://doi.org/10.1002/GPS.4103</a></p>
<p>Özge, A., Ghouri, R., Öksüz, N., &amp; Taşdelen, B. (2023). Early<br>
intervention and adding effective doses of EGb761 like Ginkgo extract<br>
slow down dementia progression: insights to the neurovascular<br>
unit.<em>Frontiers in Neurology</em>.<br>
<a href="https://doi.org/10.3389/fneur.2023.1240655">https://doi.org/10.3389/fneur.2023.1240655</a></p>
<p>Liu, Q., Wang, J., Gu, Z., Ouyang, T., Gao, H., Kan, H., &amp; Yang, Y.<br>
(2024). Comprehensive Exploration of the Neuroprotective Mechanisms<br>
of<em>Ginkgo biloba</em>Leaves in Treating Neurological Disorders.<em>The American<br>
Journal of Chinese Medicine</em>. <a href="https://doi.org/10.1142/s0192415x24500435">https://doi.org/10.1142/s0192415x24500435</a></p>
<p>Wang, J., Chen, X., Weirong, B., Wang, Z., Xiao, W., &amp; Zhu, J. (2021).<br>
Study on Mechanism of Ginkgo biloba L. Leaves for the Treatment of<br>
Neurodegenerative Diseases Based on Network Pharmacology.<em>Neurochemical<br>
Research</em>. <a href="https://doi.org/10.1007/S11064-021-03315-Z">https://doi.org/10.1007/S11064-021-03315-Z</a></p>
<p>Peng, Y., Chen, Q., Xue, Y., Jin, H., Liu, S., Du, M., &amp; Yao, S. (2024).<br>
Ginkgo biloba and Its Chemical Components in the Management of<br>
Alzheimer’s Disease.<em>The American Journal of Chinese Medicine</em>.<br>
<a href="https://doi.org/10.1142/s0192415x24500277">https://doi.org/10.1142/s0192415x24500277</a></p>
<p>S, F., M, B., G, P., &amp; Riva, A. (2023). Beneficial Effects of<br>
GinkgoselectTMPhytosomeTMon Cognitive Impairment and Oxidative Stress in<br>
Mild-Moderate Dementia.<em>Austin Alzheimer’s and Parkinson’s Disease</em>.<br>
<a href="https://doi.org/10.26420/austinalzheimersjparkinsonsdis.2023.1036">https://doi.org/10.26420/austinalzheimersjparkinsonsdis.2023.1036</a></p>
<p>Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild<br>
Neurocognitive Impairment: A Systematic Review. (2023).<em>Neuropsychiatric<br>
Disease and Treatment</em>. <a href="https://doi.org/10.2147/ndt.s401231">https://doi.org/10.2147/ndt.s401231</a></p>
<p>Napryeyenko, O., &amp; Borzenko, I. (2011). Ginkgo biloba special extract in<br>
dementia with neuropsychiatric features. A randomised,<br>
placebo-controlled, double-blind clinical trial.<em>Drug Research</em>.<br>
<a href="https://doi.org/10.1055/S-0031-1296579">https://doi.org/10.1055/S-0031-1296579</a></p>
<p>Ihl, R., Bachinskaya, N., Korczyn, A. D., Vakhapova, V., Tribanek, M.,<br>
Hoerr, R., &amp; Napryeyenko, O. (2010). Efficacy and safety of a once‐daily<br>
formulation of Ginkgo biloba extract EGb 761 in dementia with<br>
neuropsychiatric features: a randomized controlled trial.<em>International<br>
Journal of Geriatric Psychiatry</em>. <a href="https://doi.org/10.1002/GPS.2662">https://doi.org/10.1002/GPS.2662</a></p>
<p>Bachinskaya, N., Hoerr, R., &amp; Ihl, R. (2011). Alleviating<br>
neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba<br>
extract EGb 761 ® . Findings from a randomized controlled<br>
trial.<em>Neuropsychiatric Disease and Treatment</em>.<br>
<a href="https://doi.org/10.2147/NDT.S18741">https://doi.org/10.2147/NDT.S18741</a></p>
<p>Kasper, S., &amp; Schubert, H. (2009). [Ginkgo biloba extract EGb 761 in<br>
the treatment of dementia: evidence of efficacy and<br>
tolerability].<em>Fortschritte Der Neurologie Psychiatrie</em>.<br>
<a href="https://doi.org/10.1055/S-0028-1109504">https://doi.org/10.1055/S-0028-1109504</a></p>
<p>Mullaicharam, A. (2014). A Review on Evidence Based Practice of Ginkgo<br>
biloba in Brain Health.<em>International Journal of Chemical and<br>
Pharmaceutical Analysis</em>.</p>
<p>Kanowski, S., Herrmann, W. M., Stephan, K., Wierich, W., &amp; Hörr, R.<br>
(1996). Proof of Efficacy of the Ginkgo Biloba Special Extract EGb 761<br>
in Outpatients Suffering from Mild to Moderate Primary Degenerative<br>
Dementia of the Alzheimer Type or Multi-infarct<br>
Dementia.<em>Pharmacopsychiatry</em>. <a href="https://doi.org/10.1055/S-2007-979544">https://doi.org/10.1055/S-2007-979544</a></p>
<p>Loew, D. (2002). Stellenwert von Ginkgo biloba in der Behandlung der<br>
Alzheimer‐Demenz.<em>Wiener Medizinische Wochenschrift</em>.<br>
<a href="https://doi.org/10.1046/J.1563-258X.2002.02065.X">https://doi.org/10.1046/J.1563-258X.2002.02065.X</a></p>
<p>Zhu, C. G., Liu, J., Lin, J., Xu, J., &amp; Yu, E. (2024). Investigating the<br>
effects of Ginkgo biloba leaf extract on cognitive function in<br>
Alzheimer’s disease.<em>CNS Neuroscience &amp; Therapeutics</em>.<br>
<a href="https://doi.org/10.1111/cns.14914">https://doi.org/10.1111/cns.14914</a></p>
<p>Chowdhury, D., Roy, A. K., Reddy, V., Gupta, Y., Nigam, P., &amp; Hoerr, R.<br>
(2024). Multicenter, open-label, prospective study shows safety and<br>
therapeutic benefits of a defined ginkgo biloba extract for adults with<br>
Major Neurocognitive Disorder.<em>Dementia and Geriatric Cognitive<br>
Disorders</em>. <a href="https://doi.org/10.1159/000540385">https://doi.org/10.1159/000540385</a></p>
<p>Xia, C., Zhao, C., Dong, X., Yan, Z., Jiang, M., Zhu, G., &amp; Zhang, Z.<br>
(2024). Ginkgo biloba extract inhibits hippocampal neuronal injury<br>
caused by mitochondrial oxidative stress in a rat model of Alzheimer’s<br>
disease.<em>PLOS ONE</em>. <a href="https://doi.org/10.1371/journal.pone.0307735">https://doi.org/10.1371/journal.pone.0307735</a></p>
<p>Liu, L., Yue, H.-Y., Zou, J., Tang, M., Zou, F., Li, Z., Jia, Q.-Q., Li,<br>
Y.-B., Kang, J., &amp; Zuo, L. (2022). Comprehensive metabolomics and<br>
lipidomics profiling uncovering neuroprotective effects of Ginkgo biloba<br>
L. leaf extract on Alzheimer’s disease.<em>Frontiers in Pharmacology</em>.<br>
<a href="https://doi.org/10.3389/fphar.2022.1076960">https://doi.org/10.3389/fphar.2022.1076960</a></p>
<p>Li, D., Ma, J., Wei, B., Gao, S., Lang, Y., &amp; Wan, X. (2023).<br>
Effectiveness and safety of ginkgo biloba preparations in the treatment<br>
of Alzheimer’s disease: A systematic review and meta-analysis.<em>Frontiers<br>
in Aging Neuroscience</em>. <a href="https://doi.org/10.3389/fnagi.2023.1124710">https://doi.org/10.3389/fnagi.2023.1124710</a></p>
<p>Doepp, M. (2023). Ginkgo biloba: a medicinal plant with clear effects<br>
and many indications.<em>MOJ Public Health</em>.<br>
<a href="https://doi.org/10.15406/mojph.2023.12.00428">https://doi.org/10.15406/mojph.2023.12.00428</a></p>
<p>Jadhav, R. S., Patil, N. N., &amp; Saha, B. (2023). Neuroprotective<br>
activities and repair mechanisms of ginkgo biloba extract egb 761 on cns<br>
injuries and neurodegenerative disorders.<em>Innovare Journal of Medical<br>
Sciences</em>. <a href="https://doi.org/10.22159/ijms.2023.v11i2.47441">https://doi.org/10.22159/ijms.2023.v11i2.47441</a></p>
<p>Öztürk, S., &amp; Sari, A. (2023). Therapeutic Applications of Ginkgo biloba<br>
L. Tree: Systemic Review.<em>Literatür Eczacılık Bilimleri Dergisi</em>.<br>
<a href="https://doi.org/10.5336/pharmsci.2022-91528">https://doi.org/10.5336/pharmsci.2022-91528</a></p>
<p><em>Neuroprotective Effect of Ginkgo Biloba and its Role in Alzheimer’s<br>
Disease</em>. (2022). <a href="https://doi.org/10.2174/9789815050868122010015">https://doi.org/10.2174/9789815050868122010015</a></p>
<p>Singh, S., Srivastav, S., Castellani, R. J., Tomino, C., Ilari, S.,<br>
Solfrizzi, V., Malafoglia, V., Zilio, G., Russo, P., Proietti, S.,<br>
Marcolongo, F., Fermino, B. L., Milanez, M. C., Freitas, G. B. L. de,<br>
Claudio, W., Silva, F. N. da, Pereira, R. P., Rocha, J., Sartori, J., &amp;<br>
Bonini, B. (2022). Role of Ginkgo Biloba in Alzheimer<br>
Disease.<em>International Journal of Advanced Research in Science,<br>
Communication and Technology</em>. <a href="https://doi.org/10.48175/ijarsct-4963">https://doi.org/10.48175/ijarsct-4963</a></p>
<p>Zheng, Y., Xie, Y., Qi, M., Zhang, L., Wang, W., Zhang, W., Sha, L., Wu,<br>
J., Li, W., &amp; Wu, T. (2021). Ginkgo Biloba Extract Is Comparable With<br>
Donepezil in Improving Functional Recovery in Alzheimer’s Disease:<br>
Results From a Multilevel Characterized Study Based on Clinical Features<br>
and Resting-State Functional Magnetic Resonance Imaging.<em>Frontiers in<br>
Pharmacology</em>. <a href="https://doi.org/10.3389/FPHAR.2021.721216">https://doi.org/10.3389/FPHAR.2021.721216</a></p>
<p>Kandiah, N., Kandiah, N., Chan, Y. F., Chen, C., Dasig, D., Dominguez,<br>
J. C., Han, S. H., Jia, J., Kim, S., Limpawattana, P., Ng, L. L.,<br>
Nguyen, D. T., Ong, P. A., Raya-Ampil, E., Saedon, N. I., Senanarong,<br>
V., Setiati, S., Singh, H., Suthisisang, C., … Ihl, R. (2021).<br>
Strategies for the use of Ginkgo biloba extract, EGb 761®, in the<br>
treatment and management of mild cognitive impairment in Asia: Expert<br>
consensus.<em>CNS Neuroscience &amp; Therapeutics</em>.<br>
<a href="https://doi.org/10.1111/CNS.13536">https://doi.org/10.1111/CNS.13536</a></p>
<p>Tomino, C., Ilari, S., Solfrizzi, V., Malafoglia, V., Zilio, G., Russo,<br>
P., Proietti, S., Marcolongo, F., Scapagnini, G., Muscoli, C., &amp;<br>
Rossini, P. M. (2021). Mild Cognitive Impairment and Mild Dementia: The<br>
Role of Ginkgo biloba (EGb 761®).<em>Pharmaceuticals</em>.<br>
<a href="https://doi.org/10.3390/PH14040305">https://doi.org/10.3390/PH14040305</a></p>
<p>Morató, X., Tartari, J. P., Pytel, V., &amp; Boada, M. (2024a).<br>
Pharmacodynamic and Clinical Effects of Ginkgo Biloba Extract EGb 761<br>
and Its Phytochemical Components in Alzheimer’s Disease.<em>Advances in<br>
Alzheimer’s Disease</em>. <a href="https://doi.org/10.3233/aiad240022">https://doi.org/10.3233/aiad240022</a></p>
<p>Sooby, K. (2005).<em>A literature review of the efficacy of ginkgo biloba<br>
in cognitive dysfunction</em>.</p>
<p>Kaschel, R. (2009b). Ginkgo biloba: specificity of neuropsychological<br>
improvement—a selective review in search of differential<br>
effects.<em>Human Psychopharmacology-Clinical and Experimental</em>.<br>
<a href="https://doi.org/10.1002/HUP.1037">https://doi.org/10.1002/HUP.1037</a></p>
<p>Shareena, G., &amp; Kumar, D. (2022).*Traversing through half a century<br>
research timeline on Ginkgo biloba, in transforming a botanical rarity<br>
into an active functional food<br>
ingredient.*<a href="https://doi.org/10.1016/j.biopha.2022.113299">https://doi.org/10.1016/j.biopha.2022.113299</a></p>
<p>Birks, J. (2004). Is Ginkgo biloba Effective and Safe for Dementia and<br>
Cognitive Impairment.<em>Neuroepidemiology</em>.<br>
<a href="https://doi.org/10.1159/000075959">https://doi.org/10.1159/000075959</a></p>
<p>Chen, K., Shi, R., Huang, P., Guo, S., Hu, J., Han, B., Wang, P., Zou,<br>
Y., Tan, X., Lin, L., &amp; Wang, X. (2024). Ginkgolic acid inhibited Tau<br>
phosphorylation and improved cognitive ability through the SUMO-1/GSK3β<br>
pathway in Aβ-Induced Alzheimer’s disease model rats.<em>Journal of<br>
Functional Foods</em>. <a href="https://doi.org/10.1016/j.jff.2024.106183">https://doi.org/10.1016/j.jff.2024.106183</a></p>
<p>Segura, M. A. M., Torres, R. G., &amp; Delgado, S. E. B.<br>
(2000).<em>Aplicaciones clínicas del extracto de la hoja de Ginkgo biloba</em>.</p>
<p>Pagotto, G. L. de O., Santos, L. A. da S., Osman, N., Lamas, C.,<br>
Laurindo, L. F., Pomini, K. T., Guissoni, L. M., Lima, E., Goulart, R.<br>
de Á., Catharin, V. M. C. S., Direito, R., Tanaka, M., &amp; Barbalho, S. M.<br>
(2024b).<em>Ginkgo biloba: A Leaf of Hope in the Fight Against Alzheimer’s<br>
Dementia: Clinical Trial Systematic Review</em>.<br>
<a href="https://doi.org/10.20944/preprints202404.0852.v1">https://doi.org/10.20944/preprints202404.0852.v1</a></p>

